ASH Clinical News May 2016 | Page 10

The first and only rFIX therapy that
delivers high-level protection
with up to 14-day dosing*

ABOVE

5%

ZERO
BLEEDS

Factor IX (FIX) levels
above 5% over
14 days at 75 IU/kg

Median annualized
spontaneous
bleeding rate (AsBR)
of zero in 7- and 14-day
prophylaxis

UP TO

14-DAY

DOSING*

Greater freedom
from infusions

for 14 days

Visit us at IDELVION.com
*In well-controlled patients 12 years and older, defined
as 1 month without spontaneous bleeding on a weekly
dose of ≤40 IU/kg.

IDELVION is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
IDELVION® is a registered trademark of CSL Behring Recombinant Facility AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
©2016 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA
www.CSLBehring-us.com www.IDELVION.com IDL16-03-0078 4/2016

median AsBR